Drugs / Expanded Haploidentical Natural Killer cells
Expanded Haploidentical Natural Killer cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04327037 | Jan 2019 → Jun 2021 | acute lymphoblastic leukemia, acute myeloid leukemia | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded Haploidentical Natural Killer cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04327037 ↗ |
| Action | Deplete | “expanded NK cells exhibited high cytolytic activity against leukaemia cell lines” PMID 36527513 ↗ Dec 2022 |
| Modality | Cell therapy | “Expansion of NK cells with feeder cells yielded a sufficient quantity of the NK cell product to reach high cell doses or increase the frequency of cell infusions for adoptive...” PMID 36527513 ↗ Dec 2022 |
| Route | Intravenous | “expanded NK cells intravenous infusion” NCT04327037 ↗ |